AU663064B2 - Hepatitis C virus antibody - Google Patents
Hepatitis C virus antibodyInfo
- Publication number
- AU663064B2 AU663064B2 AU89457/91A AU8945791A AU663064B2 AU 663064 B2 AU663064 B2 AU 663064B2 AU 89457/91 A AU89457/91 A AU 89457/91A AU 8945791 A AU8945791 A AU 8945791A AU 663064 B2 AU663064 B2 AU 663064B2
- Authority
- AU
- Australia
- Prior art keywords
- antibody
- plasma
- virus
- hepatitis
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000711549 Hepacivirus C Species 0.000 title claims description 11
- 241000700605 Viruses Species 0.000 claims description 32
- 239000000427 antigen Substances 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 29
- 239000002245 particle Substances 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 16
- 238000003556 assay Methods 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 11
- 229920000515 polycarbonate Polymers 0.000 claims description 10
- 239000004417 polycarbonate Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 210000004408 hybridoma Anatomy 0.000 claims description 5
- 241000282579 Pan Species 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 238000010324 immunological assay Methods 0.000 claims description 2
- 208000037319 Hepatitis infectious Diseases 0.000 claims 2
- 208000005252 hepatitis A Diseases 0.000 claims 2
- 230000008105 immune reaction Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 9
- 239000012141 concentrate Substances 0.000 description 8
- 241000282577 Pan troglodytes Species 0.000 description 7
- 239000012678 infectious agent Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 238000001493 electron microscopy Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 239000011324 bead Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000010836 blood and blood product Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000617996 Human rotavirus Species 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000004513 sizing Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 240000008791 Antiaris toxicaria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 206010019786 Hepatitis non-A non-B Diseases 0.000 description 1
- 206010019791 Hepatitis post transfusion Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 238000012808 pre-inoculation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
- C07K16/109—Hepatitis C virus; Hepatitis G virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59681190A | 1990-10-12 | 1990-10-12 | |
| PCT/US1991/007571 WO1992007001A1 (en) | 1990-10-12 | 1991-10-09 | Hepatitis c virus antibody |
| US596811 | 2000-06-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU8945791A AU8945791A (en) | 1992-05-20 |
| AU663064B2 true AU663064B2 (en) | 1995-09-28 |
Family
ID=24388816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU89457/91A Expired - Fee Related AU663064B2 (en) | 1990-10-12 | 1991-10-09 | Hepatitis C virus antibody |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0552297A1 (ja) |
| JP (1) | JPH06502075A (ja) |
| KR (1) | KR930702506A (ja) |
| AU (1) | AU663064B2 (ja) |
| CA (1) | CA2093919A1 (ja) |
| TW (1) | TW216797B (ja) |
| WO (1) | WO1992007001A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0556320T3 (da) * | 1990-11-07 | 1999-10-18 | Abbott Lab | Monoklonale antistoffer mod Hepatitis C-virus og fremgangsmåde til anvendelse heraf |
| JP3217600B2 (ja) * | 1994-07-12 | 2001-10-09 | 株式会社先端生命科学研究所 | 非ａ非ｂ型肝炎ウイルス関連抗原のイムノアッセイ、それに使用するモノクローナル抗体、およびこの抗体を産生するハイブリドーマ |
| CN103965301A (zh) | 2003-04-01 | 2014-08-06 | 国家健康医学研究所 | 针对丙型肝炎病毒e1e2复合体的抗体、hcv颗粒的组合物和药物组合物 |
| US8551484B2 (en) | 2007-02-21 | 2013-10-08 | University Of Massachusetts | Human antibodies against hepatitis C virus (HCV) and uses thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0318216A1 (en) * | 1987-11-18 | 1989-05-31 | Chiron Corporation | NANBV diagnostics and vaccines |
| AU632271B2 (en) * | 1988-03-30 | 1992-12-24 | Abbott Laboratories | Production of monoclonal antibodies specific for non-a, non-b hepatitis infected liver |
| AU640920B2 (en) * | 1989-03-17 | 1993-09-09 | Novartis Vaccines And Diagnostics, Inc. | Nanbv diagnostics and vaccines |
-
1991
- 1991-10-09 EP EP91920333A patent/EP0552297A1/en not_active Withdrawn
- 1991-10-09 CA CA002093919A patent/CA2093919A1/en not_active Abandoned
- 1991-10-09 JP JP3518583A patent/JPH06502075A/ja active Pending
- 1991-10-09 KR KR1019930701073A patent/KR930702506A/ko not_active Application Discontinuation
- 1991-10-09 WO PCT/US1991/007571 patent/WO1992007001A1/en not_active Application Discontinuation
- 1991-10-09 AU AU89457/91A patent/AU663064B2/en not_active Expired - Fee Related
- 1991-11-02 TW TW080108674A patent/TW216797B/zh active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0318216A1 (en) * | 1987-11-18 | 1989-05-31 | Chiron Corporation | NANBV diagnostics and vaccines |
| AU632271B2 (en) * | 1988-03-30 | 1992-12-24 | Abbott Laboratories | Production of monoclonal antibodies specific for non-a, non-b hepatitis infected liver |
| AU640920B2 (en) * | 1989-03-17 | 1993-09-09 | Novartis Vaccines And Diagnostics, Inc. | Nanbv diagnostics and vaccines |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0552297A1 (en) | 1993-07-28 |
| KR930702506A (ko) | 1993-09-09 |
| EP0552297A4 (ja) | 1994-02-09 |
| CA2093919A1 (en) | 1992-04-13 |
| TW216797B (ja) | 1993-12-01 |
| AU8945791A (en) | 1992-05-20 |
| WO1992007001A1 (en) | 1992-04-30 |
| JPH06502075A (ja) | 1994-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69131488T2 (de) | Kombinationen der Hepatitis-C-Virus (HCV) Antigene zur Verwendung in Immuntests für Anti-HCV-Antikörper | |
| Mellors et al. | Antigen related to mammalian type-C RNA viral p30 proteins is located in renal glomeruli in human systemic lupus erythematosus. | |
| Anderson et al. | Diagnosis of human parvovirus infection by dot‐blot hybridization using cloned viral DNA | |
| JP3490085B2 (ja) | 構造エピトープを有する抗原を用いる抗ｈｃｖ抗体のイムノアッセイ | |
| US5110738A (en) | Monoclonal antibody capable of recognizing arteriosclerotic lesions and agents for detecting and treating arteriosclerosis | |
| US3994870A (en) | Purification of hepatitis B surface antigen | |
| CA1194792A (en) | Non-a, non-b hepatitis-associated monoclonal antibody and diagnostic reagent | |
| Dreesman et al. | Production of potent anti-Australia antigen sera of high specificity and sensitivity in goats | |
| KR930001278B1 (ko) | B형 간염 표면 항원(HBsAg)에 대한 모노클로널 항체의 제조방법 | |
| Hirashima et al. | Regulatory role of IgE-binding factors from rat T lymphocytes. IV. Formation of IgE-binding factors in rats treated with complete Freund's adjuvant. | |
| CA2252466C (en) | Hepatitis b monoclonal antibodies | |
| JPH08242849A (ja) | 限外濾過によるタンパク質溶液からのウイルスの除去 | |
| JPH0250426B2 (ja) | ||
| AU663064B2 (en) | Hepatitis C virus antibody | |
| EP0186360A2 (en) | Methods for preparation of highly purified, gamma globulins free of hepatitis-B-virus infectivity | |
| CA1259921A (en) | Non-a non-b hepatitis antigens | |
| KR930000186B1 (ko) | 비-a, 비-b형 간염 감염된 간에 대한 모노클로날 항체 | |
| Ma et al. | Multiple sclerosis serum and cerebrospinal fluid immunoglobulin binding to Fc receptors of oligodendrocytes | |
| EP0068465B1 (en) | Non-a, non-b hepatitis-associated antibody conjugate, the use thereof and detection reagent | |
| US4132767A (en) | Preparation of α-L antibody, purification of α-L antigen and reagent for detection of α-L antibody and α-L antigen | |
| SANTOS et al. | Trypanosoma cruzi: binding of parasite antigens to mammalian cell membranes | |
| EP0308242B1 (en) | Agglutination assay | |
| US5419906A (en) | Preparation of human immunoglobulin free of hepatitis C | |
| Buck et al. | A rapid method for the large scale preparation of bovine leukemia virus antigen | |
| US5162224A (en) | Monoclonal antibodies specific for b cells and htlv-i transformed t cells |